Downloadallstructure-activitydataforthistargetasaCSVfile

Description:CDK4/cyclinD1complexexpressedinandpurifiedfrominsectcells.Assaysusedthemethanesulfonatesaltofthecompound.
FascaplysindidnotinhibitCDK4/cyclinD2andCDK4/cyclinD3atconcentrations100M,butdidinhibitCDK6/cyclinD2butwithalowaffinityof35000nM[26].
EMDMilliporeKinaseProfilerTMscreen/ReactionBIOLOGyKinaseHotspotSMscreen
Ascreenprofiling158kinaseinhibitors(CalbiochemProteinKinaseInhibitorLibraryIandII,cataloguenumbers539744and539745)fortheirinhibitoryactivityat1Mand10Magainst234humanrecombinantkinasesusingtheEMDMilliporeKinaseProfilerTMservice.

Ascreenprofilingtheinhibitoryactivityof178commerciallyavailablekinaseinhibitorsat0.5Magainstapanelof300recombinantproteinkinasesusingtheReactionBiologyCorporationKinaseHotspotSMplatform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx
Clinically-RelevantMutationsandPathophysiology
1.AnastassiADIsT,DeaconSW,DevarajanK,MaH,PetersonJR.(2011)Comprehensiveassayofkinasecatalyticactivityrevealsfeaturesofkinaseinhibitorselectivity.
2.BehennaDC,ChenP,Freeman-CookKD,HoffmanRL,JalaieM,NagataA,NairSK,NinkovicS,OrnelasMA,PalmerCLetal..(2018)Pyridopyrimdinonecdk2/4/6inhibitors.
Patentnumber:WO2018033815A1.Assignee:PfizerInc..Prioritydate:15/08/2016.Publicationdate:22/02/2018.3.BisiJE,SorrentinoJA,RobertsPJ,TavaresFX,StrumJC.(2016)PreclinicalCharacterizationofG1T28:ANovelCDK4/6InhibitorforReductionofChemotherapy-InducedMyelosuppression.
4.BrainCT,SungMJ,LagoB.(2015)Pyrrolopyrimidinecompoundsandtheiruses.
Patentnumber:US8962630.Assignee:NovartisAg.Prioritydate:22/08/2008.Publicationdate:24/02/2015.5.BrascaMG,AmboldiN,BallinariD,CameronA,CasaleE,CerviG,ColomboM,ColottaF,CrociV,D"AlessioRetal..(2009)IdentificationofN,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide(PHA-848125),apotent,orallyavailablecyclindependentkinaseinhibitor.
6.CarlsonBA,DubayMM,SausvilleEA,BrizuelaL,WorlandPJ.(1996)FlavopiridolinducesG1arrestwithinhibitionofcyclin-dependentkinase(CDK)2andCDK4inhumanbreastcarcinomacells.
7.CirsteaD,HideshimaT,SantoL,EdaH,MishimaY,NemaniN,HuY,MimuraN,CottiniF,GorgunGetal..(2013)Small-moleculemulti-targetedkinaseinhibitorRGB-286638triggersP53-dependentand-independentanti-multiplemyelomaactivitythroughinhibitionoftranscriptionalCDKs.
8.DavisMI,HuntJP,HerrgardS,CiceriP,WodickaLM,PallaresG,HockerM,TreiberDK,ZarrinkarPP.(2011)Comprehensiveanalysisofkinaseinhibitorselectivity.
9.DayPJ,CleasbyA,TickleIJ,O"ReillyM,CoyleJE,HoldingFP,McMenaminRL,YonJ,ChopraR,LengauerCetal..(2009)CrystalstructureofhumanCDK4incomplexwithaD-typecyclin.
10.DePintoW,ChuXJ,YinX,SmithM,PackmanK,GoelzerP,LoveyA,ChenY,QianH,HamidRetal..(2006)InvitroandinvivoactivityofR547:apotentandselectivecyclin-dependentkinaseinhibitorcurrentlyinphaseIclinicaltrials.
11.DingQ,GillespieP,KimK,McComasWW,PerrottaA.(2006)Diaminothiazoleshavingantiproliferativeactivity.
Patentnumber:US7094896.Assignee:Hoffmann-LaRocheInc..Prioritydate:22/12/2001.Publicationdate:22/08/2006.12.FryDW,HarveyPJ,KellerPR,ElliottWL,MeadeM,TrachetE,AlbassamM,ZhengX,LeopoldWR,PryerNKetal..(2004)Specificinhibitionofcyclin-dependentkinase4/6byPD0332991andassociatedantitumoractivityinhumantumorxenografts.
13.GelbertLM,CaiS,LinX,Sanchez-MartinezC,DelPradoM,LallenaMJ,TorresR,AjamieRT,WishartGN,FlackRSetal..(2014)PreclinicalcharacterizationoftheCDK4/6inhibitorLY2835219:in-vivocellcycle-dependent/independentanti-tumoractivitiesalone/incombinationwithgemcitABIne.
14.GrayNS,WodickaL,ThunnissenAM,NormanTC,KwonS,EspinozaFH,MorganDO,BarnesG,LeClercS,MeijerLetal..(1998)Exploitingchemicallibraries,structure,andgenomicsinthesearchforkinaseinhibitors.
15.HoleAJ,BaumliS,ShaoH,ShiS,HuangS,PepperC,FischerPM,WangS,EndicottJA,NobleME.(2013)Comparativestructuralandfunctionalstudiesof4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrileCDK9inhibitorssuggestthebasisforisotypeselectivity.
16.JiangB,WangES,DonovanKA,LiangY,FischerES,ZhangT,GrayNS.(2019)DevelopmentofDualandSelectiveDegradersofCyclin-DependentKinases4and6.
17.JonesCD,AndrewsDM,BarkerAJ,BladesK,BythKF,FinlayMR,GehC,GreenCP,JohannsenM,WalkerMetal..(2008)Imidazolepyrimidineamidesaspotent,orallybioavailablecyclin-dependentkinaseinhibitors.
18.JordaR,HavlíčekL,ŠturcA,TuškováD,DaumováL,AlamM,ŠkerlováJ,NekardováM,PeřinaM,PospíšilTetal..(2019)3,5,7-SubstitutedPyrazolo[4,3-d]pyrimidineInhibitorsofCyclin-DependentKinasesandTheirEvaluationinLymphomaModels.
19.JordaR,HendrychováD,VollerJ,ŘezníčkováE,GuckýT,KryštofV.(2018)HowSelectiveArePharmacologicalInhibitorsofCell-Cycle-RegulatingCyclin-DependentKinases?.
20.JoshiKS,RathosMJ,JoshiRD,SivakumarM,MascarenhasM,KambleS,LalB,SharmaS.(2007)Invitroantitumorpropertiesofanovelcyclin-dependentkinaseinhibitor,P276-00.
21.KuboA,NakagawaK,VarmaRK,ConradNK,ChengJQ,LeeWC,TestaJR,JohnsonBE,KayeFJ,KelleyMJ.(1999)Thep16statusoftumorcelllinesidentifiessmallmoleculeinhibitorsspecificforcyclin-dependentkinase4.
22.LaneME,YuB,RiceA,LipsonKE,LiangC,SunL,TangC,McMahonG,PestellRG,WadlerS.(2001)Anovelcdk2-selectiveinhibitor,SU9516,inducesapoptosisincoloncarcinomacells.
23.PaivaC,GodbersenJC,SoderquistRS,RowlandT,KilmarxS,SpurgeonSE,BrownJR,SrinivasaSP,DanilovAV.(2015)Cyclin-DependentKinaseInhibitorP1446AInducesApoptosisinaJNK/p38MAPK-DependentMannerinChronicLymphocyticLeukemiaB-Cells.
24.PennatiM,CampbellAJ,CurtoM,BindaM,ChengY,WangLZ,CurtinN,GoldingBT,GriffinRJ,HardcastleIRetal..(2005)Potentiationofpaclitaxel-inducedapoptosisbythenovelcyclin-dependentkinaseinhibitorNU6140:apossIBLeroleforsurvivindown-regulation.
25.RyuCK,KangHY,LeeSK,NamKA,HongCY,KoWG,LeeBH.(2000)5-Arylamino-2-methyl-4,7-dioxobenzothiazolesasinhibitorsofcyclin-dependentkinase4andcytotoxicagents.
26.SoniR,MullerL,FuretP,SchoepferJ,StephanC,Zumstein-MeckerS,FretzH,ChaudhuriB.(2000)Inhibitionofcyclin-dependentkinase4(Cdk4)byfascaplysin,amarinenaturalproduct.
27.SquiresMS,FeltellRE,WallisNG,LewisEJ,SmithDM,CrossDM,LyonsJF,ThompsonNT.(2009)BiologicalcharacterizationofAT7519,asmall-moleculeinhibitorofcyclin-dependentkinases,inhumantumorcelllines.
28.StrumJC,BisiJE,RobertsPJ,TavaresFX.(2016)Transientprotectionofnormalcellsduringchemotherapy.
Patentnumber:US9464092B2.Assignee:G1TherapeuticsInc.Prioritydate:15/03/2013.Publicationdate:11/10/2016.29.WodickaLM,CiceriP,DavisMI,HuntJP,FloydM,SalernoS,HuaXH,FordJM,ArmstrongRC,ZarrinkarPPetal..(2010)Activationstate-dependentbindingofsmallmoleculekinaseinhibitors:structuralinsightsfrombiochemistry.
30.ZhuG,ConnerSE,ZhouX,ShihC,LiT,AndersonBD,BrooksHB,CampbellRM,ConsidineE,DempseyJAetal..(2003)Synthesis,structure-activityrelationship,andbiologicalstudiesofindolocarbazolesaspotentcyclinD1-CDK4inhibitors.
CDK4subfamily:cyclindependentkinase4.Lastmodifiedon12/11/2019.Accessedon18/05/2020.IUPHAR/BPSGuidetoPHARMACOLOGY,http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976.